Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Immunol.

Sec. Vaccines and Molecular Therapeutics

Development of Human Mycoplasma Vaccines: Navigating the IL-17A Paradox

Provisionally accepted
  • 1University Library, Xiangnan University, Chenzhou, China
  • 2The First People's Hospital of Changde City, Changde, China

The final, formatted version of the article will be published soon.

Despite decades of effort, effective vaccines against pathogenic human mycoplasmas remain elusive, largely due to vaccine-enhanced disease (VED). Recent discoveries highlight the paradoxical role of interleukin-17A (IL-17A) as both protector and instigator of pathology. Although IL-17A is indispensable for mucosal defense against many pathogens, its dysregulated expression following mycoplasma vaccination can provoke excessive neutrophilic inflammation and exacerbate pulmonary injury. This review synthesizes emerging evidence implicating bacterial lipoproteins as key triggers of maladaptive IL-17A responses. We delineate the duality of IL-17A in mycoplasma infections, mediating both protection and tissue damage, and critically examine its implications for vaccine design. Integrating insights from recent animal models, B-cell depletion studies, and proteomic analyses, we propose a framework for next-generation vaccines that elicit protective immunity while circumventing IL-17A-driven immunopathology.

Keywords: Mycoplasmas, Interleukin-17A (IL-17A), Vaccines, vaccine-enhanced disease (VED), antibody

Received: 08 Oct 2025; Accepted: 21 Nov 2025.

Copyright: © 2025 Guo, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Fangyi Guo, guofy97@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.